Back to top
more

HCA Healthcare (HCA)

(Real Time Quote from BATS)

$369.48 USD

369.48
51,064

+3.33 (0.91%)

Updated Aug 7, 2025 10:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Tenet Healthcare Corporation (THC) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Nilanjan Choudhury headshot

Bet on These 5 Attractive Relative Price Strength Plays

by Nilanjan Choudhury

STX, RGA, HCA, IP and OSW are five stocks with explosive relative price strength.

Zacks Equity Research

Tenet (THC) Q2 Earnings Beat on Patient Volumes, '24 EPS View Up

by Zacks Equity Research

Tenet Healthcare's (THC) Q2 results reflect net revenue per case growth, higher pricing yield and a decline in overall expenses. It expects 2024 adjusted EPS within $10.41-$11.12, up from the previous guidance of $8.37-$9.41.

Shaun Pruitt headshot

2 Standout Stocks to Buy After Beating Earnings Expectations

by Shaun Pruitt

Now looks like a promising time to invest in the increased profitability of HCA Healthcare (HCA) and Spotify Technology (SPOT) after beating Q2 earnings expectations on Tuesday.

Zacks Equity Research

HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View

by Zacks Equity Research

HCA Healthcare (HCA) increases its 2024 EPS in the range of $21.60-$22.8, the midpoint implying growth of 17% from the 2023 figure.

Zacks Equity Research

Compared to Estimates, HCA (HCA) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

HCA Healthcare (HCA) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

HCA (HCA) delivered earnings and revenue surprises of 10.66% and 2.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.

Zacks Equity Research

Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings

by Zacks Equity Research

IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

Zacks Equity Research

Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how HCA Healthcare (HCA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

Zacks Equity Research

Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release

by Zacks Equity Research

Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.

Kaibalya Pravo Dey headshot

Buying Tenet (THC) Pre-Q2 Earnings: A Prescription for Profits?

by Kaibalya Pravo Dey

Tenet Healthcare's (THC) second-quarter earnings are likely to have benefited from higher admissions, average length of stay and patient days.

Zacks Equity Research

Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings

by Zacks Equity Research

Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.

Zacks Equity Research

What's in Store for Texas Instruments (TXN) in Q2 Earnings?

by Zacks Equity Research

Texas Instruments' (TXN) second-quarter 2024 results are likely to reflect the adverse impacts of a weak demand environment and increasing manufacturing costs.

Zacks Equity Research

4 Healthcare Stocks Poised to Beat Q2 Earnings Estimates

by Zacks Equity Research

Expanding aging population and the increasing demand for affordable health products are likely to have boosted the performance of healthcare stocks in Q2. CI, UHS, HCA & THC are potential outperformers.

Zacks Equity Research

Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?

by Zacks Equity Research

Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.

Zacks Equity Research

Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings

by Zacks Equity Research

Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.

Zacks Equity Research

Can HCA Healthcare (HCA) Beat Q2 Earnings on Growing Admissions?

by Zacks Equity Research

HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.

Zacks Equity Research

Will Patient Volumes Drive Universal Health's (UHS) Q2 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q2 performance is likely to gain from strong performances in its Acute Care Hospital Services and Behavioral Health Care Services segments.

Zacks Equity Research

Tenet Healthcare (THC) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings

by Zacks Equity Research

Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.

Zacks Equity Research

UnitedHealth Group (UNH) Q2 Earnings Beat on Strong Optum Unit

by Zacks Equity Research

UnitedHealth Group's (UNH) second-quarter earnings continue to be supported by strong Optum and UnitedHealthcare business lines. Rising medical costs partially offset the positives.

Zacks Equity Research

HCA Healthcare (HCA) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.